Bambusa Therapeutics (BBTX) sets $15-$17 range for $150 million Nasdaq IPO
As seen on the 24/7 Wall St. homepage on October 26, 2026.
Bambusa sets $15-$17 range for $150 million Nasdaq IPO
Bambusa Therapeutics just put a number on its Nasdaq debut: 9.375 million shares at $15 to $17, a $150 million raise with BofA Securities, Evercore ISI, UBS and Cantor running the books. Terms are set, so pricing is days away for anyone who wants in before it trades.
Continue ReadingShow less
Bambusa Therapeutics has filed amended terms for its initial public offering, targeting gross proceeds of $150 million. The amended SEC filing sets the terms, which typically means pricing is a matter of days away.
BofA Securities, Evercore ISI, UBS, and Cantor are running the books on the deal, a roster of underwriters that signals institutional distribution reach for the offering. Investors who want exposure ahead of the first trade need to act before pricing clears, since allocations are decided in that window.
The shares are proposed for listing on the Nasdaq. Once the final price is confirmed and trading begins, early IPO allocations are locked in and the open-market price takes over.
For investors tracking the IPO pipeline, this amended filing represents the last major public data point before Bambusa goes live. The SEC filing linked below contains the full terms and risk disclosures for anyone doing deeper diligence before pricing.